Ashwin A. Patkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ashwin A. Patkar has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Chi-Un Pae
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
20 shared publications - Changsu Han
Department of Psychiatry, Korea University College of Medicine, Seoul, Korea
16 shared publications - Prakash S. Masand
Duke-NUS Medical School, Singapore
15 shared publications - Soo-Jung Lee
Department of Psychiatry, the Catholic University of Korea College of Medicine, Seoul, Korea
9 shared publications - Won-Myong Bahk
The Catholic University of Korea
7 shared publications - Cheolmin Shin
Department of Psychiatry, Korea University College of Medicine, Seoul, Korea
4 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (3) , 627-640
A Claims Data–Based Comparison of Treatment Continuation between Aripiprazole Once-monthly and Paliperidone Palmitate in Routine Practice
- 3 July 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (3) , 627-640
Open AccessA Claims Data–Based Comparison of Treatment Continuation between Aripiprazole Once-monthly and Paliperidone Palmitate in Routine Practice
- Open Access
- 1 July 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (4) , 701-713
Two-injection Start Strategy of Aripiprazole Once-monthly Injection: Current Evidence and Clinical Implications
- 1 July 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (4) , 701-713
Open AccessTwo-injection Start Strategy of Aripiprazole Once-monthly Injection: Current Evidence and Clinical Implications
- Open Access
- 30 December 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (1) , 15-29
Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease: Clinical Perspectives
Hayeon Kim, Kyung Ho Lee, Changsu Han, Ashwin A. Patkar, Prakash S. Masand, Won-Myong Bahk, Chi-Un Pae. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.24.1252
- 30 December 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (1) , 15-29
Open AccessBrexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease: Clinical Perspectives
Hayeon Kim, Kyung Ho Lee, Changsu Han, Ashwin A. Patkar, Prakash S. Masand, Won-Myong Bahk, Chi-Un Pae. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.24.1252
- Open Access
- 4 February 2024
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 22 (2) , 370-375
The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting
Seung-Hoon Lee, Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae. Clin Psychopharmacol Neurosci 2024;22:370-5. https://doi.org/10.9758/cpn.23.1106
- 4 February 2024
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 22 (2) , 370-375
Open AccessThe Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting
Seung-Hoon Lee, Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae. Clin Psychopharmacol Neurosci 2024;22:370-5. https://doi.org/10.9758/cpn.23.1106
- Open Access
- 6 September 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 22 (2) , 253-262
Effect of Frailty on Depression among Patients with Late-life Depression: A Test of Anger, Anxiety, and Resilience as Mediators
Junhyung Kim, Hyun-Ghang Jeong, Moon-Soo Lee, Chi-Un Pae, Ashwin A. Patkar, Sang Won Jeon, Cheolmin Shin, Changsu Han. Clin Psychopharmacol Neurosci 2024;22:253-62. https://doi.org/10.9758/cpn.23.1070
- 6 September 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 22 (2) , 253-262
Open AccessEffect of Frailty on Depression among Patients with Late-life Depression: A Test of Anger, Anxiety, and Resilience as Mediators
Junhyung Kim, Hyun-Ghang Jeong, Moon-Soo Lee, Chi-Un Pae, Ashwin A. Patkar, Sang Won Jeon, Cheolmin Shin, Changsu Han. Clin Psychopharmacol Neurosci 2024;22:253-62. https://doi.org/10.9758/cpn.23.1070
- Open Access
- 31 August 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 21 (3) , 594-598
Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae. Clin Psychopharmacol Neurosci 2023;21:594-8. https://doi.org/10.9758/cpn.23.1060
- 31 August 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 21 (3) , 594-598
Open AccessAdditional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae. Clin Psychopharmacol Neurosci 2023;21:594-8. https://doi.org/10.9758/cpn.23.1060
- Open Access
- 28 February 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 21 (1) , 135-146
Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
Cheolmin Shin, Sang Won Jeon, Seung-Hoon Lee, Chi-Un Pae, Narei Hong, Hyun Kook Lim, Ashwin A. Patkar, Prakash S. Masand, Hyonggin An, Changsu Han. Clin Psychopharmacol Neurosci 2023;21:135-46. https://doi.org/10.9758/cpn.2023.21.1.135
- 28 February 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 21 (1) , 135-146
Open AccessEfficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
Cheolmin Shin, Sang Won Jeon, Seung-Hoon Lee, Chi-Un Pae, Narei Hong, Hyun Kook Lim, Ashwin A. Patkar, Prakash S. Masand, Hyonggin An, Changsu Han. Clin Psychopharmacol Neurosci 2023;21:135-46. https://doi.org/10.9758/cpn.2023.21.1.135
- Open Access
- 25 April 2022
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 19 (4) , 268-280
Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
Objective This study aimed to compare the efficacy and safety of escitalopram, vortioxetine, and desvenlafaxine for acute treatment of major depressive disorder (MDD) with cognitive complaint (CC).Methods A total of 129 patients with MDD who also complained of CC were randomized evenly to either escitalopram, vortioxetine, or desvenlafaxine group and underwent a multi-center, six-week, rater-blinded, and head-to-head comparative trial. Differences in depressive symptoms following treatment were measured using the Hamilton Depression Rating Scale (HAMD) and the Montgomery-Åsberg Depression Rating Scale (MADRS). Subjective cognitive function and the presence of adverse events were assessed.Results The three antidepressant treatment groups did not show significant differences in the improvement of depressive symptoms as measured by HAMD and MADRS. Desvenlafaxine treatment was associated with a superior treatment response rate in depressive symptoms compared to vortioxetine or escitalopram treatment. However, no significant differences were found in the remission rate of depressive symptoms. The three antidepressant treatment groups did not show significant differences in the improvement of CC. Adverse profiles of each treatment group were tolerable, with no significant differences.Conclusion In acute antidepressant treatment for MDD with CC, escitalopram, vortioxetine, and desvenlafaxine presented similar efficacy in relief of depressive symptoms; however, desvenlafaxine was associated with a superior treatment. Further studies are needed to confirm these results by investigating the therapeutic efficacy and safety profile of long-term antidepressant treatment of MDD with CC (Clinical Trial Registry, http://cris.nih.go.kr/cris/en/: KCT0002173).
- 25 April 2022
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 19 (4) , 268-280
Open AccessAcute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
Objective This study aimed to compare the efficacy and safety of escitalopram, vortioxetine, and desvenlafaxine for acute treatment of major depressive disorder (MDD) with cognitive complaint (CC).Methods A total of 129 patients with MDD who also complained of CC were randomized evenly to either escitalopram, vortioxetine, or desvenlafaxine group and underwent a multi-center, six-week, rater-blinded, and head-to-head comparative trial. Differences in depressive symptoms following treatment were measured using the Hamilton Depression Rating Scale (HAMD) and the Montgomery-Åsberg Depression Rating Scale (MADRS). Subjective cognitive function and the presence of adverse events were assessed.Results The three antidepressant treatment groups did not show significant differences in the improvement of depressive symptoms as measured by HAMD and MADRS. Desvenlafaxine treatment was associated with a superior treatment response rate in depressive symptoms compared to vortioxetine or escitalopram treatment. However, no significant differences were found in the remission rate of depressive symptoms. The three antidepressant treatment groups did not show significant differences in the improvement of CC. Adverse profiles of each treatment group were tolerable, with no significant differences.Conclusion In acute antidepressant treatment for MDD with CC, escitalopram, vortioxetine, and desvenlafaxine presented similar efficacy in relief of depressive symptoms; however, desvenlafaxine was associated with a superior treatment. Further studies are needed to confirm these results by investigating the therapeutic efficacy and safety profile of long-term antidepressant treatment of MDD with CC (Clinical Trial Registry, http://cris.nih.go.kr/cris/en/: KCT0002173).
- Open Access
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 600-609
Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
Jung-Jin Kim, Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand. Clin Psychopharmacol Neurosci 2021;19:600-9. https://doi.org/10.9758/cpn.2021.19.4.600
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 600-609
Open AccessExploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
Jung-Jin Kim, Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand. Clin Psychopharmacol Neurosci 2021;19:600-9. https://doi.org/10.9758/cpn.2021.19.4.600
- Open Access
- 31 August 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (3) , 434-448
Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand. Clin Psychopharmacol Neurosci 2021;19:434-48. https://doi.org/10.9758/cpn.2021.19.3.434
- 31 August 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (3) , 434-448
Open AccessConsideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand. Clin Psychopharmacol Neurosci 2021;19:434-48. https://doi.org/10.9758/cpn.2021.19.3.434